Wave Life Sciences Ltd. Files 2023 Annual Report on Form 10-K

Ticker: WVE · Form: 10-K · Filed: Mar 6, 2024 · CIK: 1631574

Wave Life Sciences Ltd. 10-K Filing Summary
FieldDetail
CompanyWave Life Sciences Ltd. (WVE)
Form Type10-K
Filed DateMar 6, 2024
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$0, $20 million, $505 million
Sentimentneutral

Sentiment: neutral

Topics: 10-K, Wave Life Sciences, Annual Report, Pharmaceuticals, Biotechnology

TL;DR

<b>Wave Life Sciences Ltd. has filed its 2023 annual report (10-K) detailing its financial performance and business operations for the year ending December 31, 2023.</b>

AI Summary

Wave Life Sciences Ltd. (WVE) filed a Annual Report (10-K) with the SEC on March 6, 2024. Wave Life Sciences Ltd. filed its 2023 Form 10-K on March 6, 2024. The filing covers the fiscal year ending December 31, 2023. The company's principal business address is in Singapore, with a mailing address in Cambridge, MA. The filing references various equity incentive plans and stock options. Key dates include the fiscal year end of December 31, 2023, and the filing date of March 6, 2024.

Why It Matters

For investors and stakeholders tracking Wave Life Sciences Ltd., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Wave Life Sciences' financial health, operational activities, and strategic direction for investors and stakeholders. The detailed information within the filing is crucial for understanding the company's current standing, potential risks, and future prospects in the pharmaceutical preparations industry.

Risk Assessment

Risk Level: medium — Wave Life Sciences Ltd. shows moderate risk based on this filing. The company operates in the pharmaceutical preparations industry, which is subject to significant regulatory oversight, clinical trial risks, and competitive pressures, as indicated by the numerous references to equity incentive plans and collaborations.

Analyst Insight

Review the detailed financial statements and risk factors in the 10-K to assess the company's financial stability and future growth potential.

Key Numbers

  • 2023-12-31 — Fiscal Year End (Period covered by the 10-K filing)
  • 2024-03-06 — Filing Date (Date the 10-K was submitted to the SEC)
  • 218 — Value 1 (Associated with specific plan or program)
  • 466 — Value 2 (Associated with specific plan or program)
  • 346 — Value 3 (Associated with specific plan or program)
  • 289 — Value 4 (Associated with specific plan or program)

Key Players & Entities

  • Wave Life Sciences Ltd. (company) — Filer of the 10-K
  • Takeda Pharmaceutical Company Limited (company) — Mentioned in relation to collaboration agreements
  • GSK (company) — Mentioned in relation to equity investment
  • Christopher Francis (person) — Mentioned in relation to specific dates

FAQ

When did Wave Life Sciences Ltd. file this 10-K?

Wave Life Sciences Ltd. filed this Annual Report (10-K) with the SEC on March 6, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by Wave Life Sciences Ltd. (WVE).

Where can I read the original 10-K filing from Wave Life Sciences Ltd.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Wave Life Sciences Ltd..

What are the key takeaways from Wave Life Sciences Ltd.'s 10-K?

Wave Life Sciences Ltd. filed this 10-K on March 6, 2024. Key takeaways: Wave Life Sciences Ltd. filed its 2023 Form 10-K on March 6, 2024.. The filing covers the fiscal year ending December 31, 2023.. The company's principal business address is in Singapore, with a mailing address in Cambridge, MA..

Is Wave Life Sciences Ltd. a risky investment based on this filing?

Based on this 10-K, Wave Life Sciences Ltd. presents a moderate-risk profile. The company operates in the pharmaceutical preparations industry, which is subject to significant regulatory oversight, clinical trial risks, and competitive pressures, as indicated by the numerous references to equity incentive plans and collaborations.

What should investors do after reading Wave Life Sciences Ltd.'s 10-K?

Review the detailed financial statements and risk factors in the 10-K to assess the company's financial stability and future growth potential. The overall sentiment from this filing is neutral.

Risk Factors

  • Regulatory Risks [medium — regulatory]: The company is subject to extensive regulation by governmental authorities, which can impact product development, approval, and marketing.
  • Market Competition [medium — market]: The pharmaceutical and biotechnology markets are highly competitive, with potential for new entrants and rapid technological advancements.
  • Funding and Liquidity [medium — financial]: The company's ability to fund its operations and research and development activities depends on its access to capital and its financial resources.
  • Reliance on Key Personnel [low — operational]: The success of the company may depend on the continued service of its key scientific and management personnel.

Key Dates

  • 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K.
  • 2024-03-06: Filing Date — Date the 10-K was officially submitted to the SEC.

Glossary

10-K
An annual report required by the U.S. Securities and Exchange Commission (SEC), which gives a comprehensive summary of a company's financial performance. (This filing provides the core financial and operational data for Wave Life Sciences Ltd. for the fiscal year 2023.)

Filing Stats: 4,427 words · 18 min read · ~15 pages · Grade level 16.9 · Accepted 2024-03-06 07:55:36

Key Financial Figures

  • $0 — of each exchange on which registered $0 Par Value Ordinary Shares WVE The N
  • $20 million — collaboration with GSK, resulting in a $20 million payment. Under the terms of the collabo
  • $505 million — ation, we are eligible to receive up to $505 million in additional development, launch, and

Filing Documents

Business

Business 6 Item 1A.

Risk Factors

Risk Factors 61 Item 1B. Unresolved Staff Comments 98 Item 1C. Cybersecurity 98 Item 2.

Properties

Properties 99 Item 3.

Legal Proceedings

Legal Proceedings 99 Item 4. Mine Safety Disclosures 99 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 100 Item 6. [Reserved] 100 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 101 Item 7A.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 111 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 111 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 111 Item 9A.

Controls and Procedures

Controls and Procedures 112 Item 9B. Other Information 113 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 113 PART III Item 10. Directors, Executive Officers and Corporate Governance 114 Item 11.

Executive Compensation

Executive Compensation 114 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 114 Item 13. Certain Relationships and Related Transactions, and Director Independence 114 Item 14. Principal Accountant Fees and Services 114 PART IV Item 15. Exhibits and Financial Statement Schedules 115 Item 16. Form 10-K Summary 119

Signatures

Signatures 120 ii Special Note Regarding Forward-Looking Statements This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), that relate to future events or to our future operations or financial performance. Any forward-looking statement involves known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statement. In some cases, forward-looking statements are identified by the words "anticipate," "believe," "continue," "could," "estimate," "expect," "future," "goals," "intend," "likely," "may," "might," "ongoing," "objective," "plan," "potential," "predict," "project," "seek," "should," "strategy," "target," "will" and "would" or the negative of these terms, or other comparable terminology intended to identify statements about the future, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements, other than statements of historical fact, about, among other things: our ability to fund our future operations; our financial position, revenues, costs, expenses, uses of cash and capital requirements; our need for additional financing or the period for which our existing cash resources will be sufficient to meet our operating requirements; the success, progress, number, scope, cost, duration, timing or results of our research and development activities, preclinical studies and clinical trials, including the timing for initiation or completion of or availability of results from any preclinical studies and clinical trials or for submission, review or approval of any regulatory filing; the t

Business

Item 1. Business Overview We are a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines (also known as oligonucleotides), or those targeting ribonucleic acid ("RNA"), to transform human health. Our RNA medicines platform, PRISM TM , combines multiple modalities, chemistry innovation and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Our toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing and RNA interference ("RNAi"), providing us with unique capabilities for designing and sustainably delivering candidates that optimally address disease biology. Our lead programs are in rare and prevalent diseases, including alpha-1 antitrypsin deficiency ("AATD"), obesity, Duchenne muscular dystrophy ("DMD"), and Huntington's disease ("HD"). We were founded on the recognition that there was a significant, untapped opportunity to use chemistry innovation to tune the pharmacological properties of oligonucleotides. Today, we have more than a decade of experience challenging convention related to oligonucleotide design and pioneering novel chemistry modifications to optimize the pharmacological properties of our molecules. We have seen preclinically and in clinical trials that these chemistry modifications enhance potency, distribution, and durability of effect of our molecules. Our novel chemistry also allows us to avoid using complex delivery vehicles, such as lipid nanoparticles and viruses, and instead use clinically proven conjugates (e.g. N -acetylgalactosamine or ("GalNAc")) or free uptake for delivery to a variety of cell and tissue types. We maintain strong and broad intellectual property, including for our novel chemistry modifications. Our best-in-class chemistry capabilities have also unlocked new areas of biology, such as harnessing adenosine deaminases acting on RNA ("ADAR") enzymes for messenger RNA ("mRNA") correction

View Full Filing

View this 10-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.